Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29906252

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2019 Aug 20
First author
Cho J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Cho J
      type
      Author
    2. name
      Kim HS
      type
      Author
    3. name
      Ku BM
      type
      Author
    4. name
      Choi YL
      type
      Author
    5. name
      Cristescu R
      type
      Author
    6. name
      Han J
      type
      Author
    7. name
      Sun JM
      type
      Author
    8. name
      Lee SH
      type
      Author
    9. name
      Ahn JS
      type
      Author
    10. name
      Park K
      type
      Author
    11. name
      Ahn MJ
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Cho J
      type
      Author
    2. name
      Kim HS
      type
      Author
    3. name
      Ku BM
      type
      Author
    4. name
      Choi YL
      type
      Author
    5. name
      Cristescu R
      type
      Author
    6. name
      Han J
      type
      Author
    7. name
      Sun JM
      type
      Author
    8. name
      Lee SH
      type
      Author
    9. name
      Ahn JS
      type
      Author
    10. name
      Park K
      type
      Author
    11. name
      Ahn MJ
      type
      Author
    bibliography ids
    1. nci-bib-a0de509cb6e4853535a74e73
    book metadata
    content sha256
    22e390de6277184c476d7f3676945f35eb7b42637bcacf7d800775ac2d94ce43
    document type
    citation
    dois
    1. 10.1200/JCO.2017.77.3184
    electronic publication date
    display
    2018 Jun 15
    precision
    day
    year
    2018
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:29906252
    immutable id
    pubmed:29906252@22e390de6277184c476d7f3676945f35eb7b42637bcacf7d800775ac2d94ce43
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    24
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    2162-2170
    volume
    37
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      29906252
      provenance
      batch id
      c4c0356d060413f719c2
      provider
      NCBI PubMed ESummary
      record sha256
      6ff30316083fc0423290524d911998284a49623a11734a98a2dc5e4f23ab9c10
      response sha256
      adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
      retrieved at
      2026-09-09T23:47:33.674758+00:00
      publication date
      display
      2019 Aug 20
      precision
      day
      year
      2019
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/29906252/
      title
      Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

      Preserved source evidence · Not medical advice